2022-RA-1309-ESGO Analysis of the prognostic value of systemic inflammation markers obtained from the complete blood count in patients treated for advanced ovarian carcinoma at the CUN in the period 2000–2015. (20th October 2022)
- Record Type:
- Journal Article
- Title:
- 2022-RA-1309-ESGO Analysis of the prognostic value of systemic inflammation markers obtained from the complete blood count in patients treated for advanced ovarian carcinoma at the CUN in the period 2000–2015. (20th October 2022)
- Main Title:
- 2022-RA-1309-ESGO Analysis of the prognostic value of systemic inflammation markers obtained from the complete blood count in patients treated for advanced ovarian carcinoma at the CUN in the period 2000–2015
- Authors:
- Jiménez, Jaime Espinós
Aramendía Beitia, José Manuel
Chacón, Matías Jurado
Mínguez Milio, José Ángel
Chiva, Luis
Eslava, Marta Santisteban
Villamayor, Julia
Lorenzo, Luisa Sánchez
Vazquez, Daniel
Castellanos, Teresa
Boria, Félix
Chacón, Enrique
Alcázar, Andrés
Sancho, Lidia
Iscar, Teresa
Martín, Antonio González
Alcázar Zambrano, Juan Luis - Abstract:
- Abstract : Introduction/Background: Markers of systemic inflammation have been described as prognostic factors in epithelial ovarian cancer (EOC). We aimed to retrospectively explore these new markers in our patient population and define its relationship with prognosis. Methodology: Medical records of patients with newly diagnosed FIGO stage III – IV EOC between 2000 and 2015 were reviewed. We examined the red cell distribution width (RDW), mean platelet volume (MPV), neutrophil to lymphocyte (NLR), monocyte to lymphocyte (MLR), and platelet to lymphocyte (PLR) ratios at diagnosis. Results: 77 patients were analyzed. Mean age 58.3 years. FIGO IIIC 56%, serous 87% (80% high grade). 69% had primary surgery, 47% optimal citorreduction. Relevant values at diagnosis: median RDW 13.7 (IQR 12.8 – 14.8), median MPV 8.6 fl (IQR 8.1 – 9.5), median NLR 3.4 (IQR 2.3 – 4–5), median MLR 0.3 (IQR 0.25 – 0.45), median PLR 217.5 (IQR 151.5 – 309.6). Survival analysis: Median PFS 21.8 months, CI95% 18.8 – 77.5. Median OS 74.4 months (CI95% 51.6 – 123.6). Multivariate Cox OS analysis: MLR≥0.245 was a risk factor for OS, HR 7.04, p=0.059 Univariate Cox PFS analysis: MLR at diagnosis >0.32 predicted worse PFS, 19.2 vs 31.7 months, p<0.001, HR 3.49. PLR at diagnosis >289.1 predicted worse PFS, 19.2 vs 24.8 months, p=0.01, HR 2. On multivariate PFS analysis none of the variables retained its significance. Conclusion: In our series, higher MLR at diagnosis predicted worse outcomes in FIGO III – IVAbstract : Introduction/Background: Markers of systemic inflammation have been described as prognostic factors in epithelial ovarian cancer (EOC). We aimed to retrospectively explore these new markers in our patient population and define its relationship with prognosis. Methodology: Medical records of patients with newly diagnosed FIGO stage III – IV EOC between 2000 and 2015 were reviewed. We examined the red cell distribution width (RDW), mean platelet volume (MPV), neutrophil to lymphocyte (NLR), monocyte to lymphocyte (MLR), and platelet to lymphocyte (PLR) ratios at diagnosis. Results: 77 patients were analyzed. Mean age 58.3 years. FIGO IIIC 56%, serous 87% (80% high grade). 69% had primary surgery, 47% optimal citorreduction. Relevant values at diagnosis: median RDW 13.7 (IQR 12.8 – 14.8), median MPV 8.6 fl (IQR 8.1 – 9.5), median NLR 3.4 (IQR 2.3 – 4–5), median MLR 0.3 (IQR 0.25 – 0.45), median PLR 217.5 (IQR 151.5 – 309.6). Survival analysis: Median PFS 21.8 months, CI95% 18.8 – 77.5. Median OS 74.4 months (CI95% 51.6 – 123.6). Multivariate Cox OS analysis: MLR≥0.245 was a risk factor for OS, HR 7.04, p=0.059 Univariate Cox PFS analysis: MLR at diagnosis >0.32 predicted worse PFS, 19.2 vs 31.7 months, p<0.001, HR 3.49. PLR at diagnosis >289.1 predicted worse PFS, 19.2 vs 24.8 months, p=0.01, HR 2. On multivariate PFS analysis none of the variables retained its significance. Conclusion: In our series, higher MLR at diagnosis predicted worse outcomes in FIGO III – IV patients. … (more)
- Is Part Of:
- International journal of gynecological cancer. Volume 32(2022)Supplement 2
- Journal:
- International journal of gynecological cancer
- Issue:
- Volume 32(2022)Supplement 2
- Issue Display:
- Volume 32, Issue 2 (2022)
- Year:
- 2022
- Volume:
- 32
- Issue:
- 2
- Issue Sort Value:
- 2022-0032-0002-0000
- Page Start:
- A321
- Page End:
- A321
- Publication Date:
- 2022-10-20
- Subjects:
- Generative organs, Female -- Cancer -- Periodicals
616.99465 - Journal URLs:
- http://journals.lww.com/ijgc/pages/default.aspx ↗
http://www3.interscience.wiley.com/journal/118544021/toc ↗
https://ijgc.bmj.com/ ↗
http://journals.lww.com ↗ - DOI:
- 10.1136/ijgc-2022-ESGO.684 ↗
- Languages:
- English
- ISSNs:
- 1048-891X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.273500
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 24569.xml